Semaglutide and alcohol: what is actually documented

Posting this under the heading it deserves: Semaglutide and alcohol: what is actually documented Everything below is what sits behind that.

I would like to know what people here actually do about semaglutide and alcohol, as distinct from what is usually recommended. Those have diverged in every other subject I have looked at closely.

Mine is below, with the reasoning, including the parts I am not confident about.

Where I part company with the opening post, and it is a narrow parting.

Agreed on semaglutide and alcohol, with one qualification that I think matters. The reasoning holds for the case as described. Change the starting assumption and it does not, and the starting assumption is the part nobody states.

Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.

On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.

The short answer was in the first line; everything after is the working.

I came in to disagree and I am leaving without a disagreement.

I had written a reply contradicting post #2 and deleted it. Here is what survived.

Research-use-only semaglutide is not a licensed medicine, is not manufactured to pharmaceutical standards, and is not approved for human use. That is a statement about what it is, not a coded opinion about anything.

Stating my assumptions rather than smuggling them in.

Adding the measurement that post #4 says would settle it.

Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.

Two people in this thread mean different things by semaglutide and alcohol and are disagreeing about the definition while believing they are disagreeing about the facts. Worth pausing to define it.

Post #8 is right about the mechanism and I think understates the practical bit.

The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice. Visible particles or frank cloudiness is different and would be reason to contact the supplier.

One more caveat and then I will stop qualifying: the sample selected itself.

On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.

I would want the raw data before agreeing with my own summary of it.

On post #9 — agreed on the reasoning, with one qualification.

Adding a small correction to the semaglutide and alcohol summary above rather than a disagreement with it. The substance holds; one of the figures is out by a factor that matters.

Picking up post #9: that is the part I would want checked first.

The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

I am describing what is, rather than arguing for what should be.

On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval is not arbitrary — it is what stops two doses stacking inside one absorption window.

Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.

Anyone with a larger sample, please post it.